Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Abemaciclib biedt nieuw perspectief bij de behandeling van gevorderde HR+ HER2- borstkanker
nov 2019 | Borstkanker